文献速递鼻科

贝伐珠单抗治疗遗传性出血性毛细血管扩张症所致家族性鼻出血的效果

[Effects of bevacizumab on familial epistaxis caused by hereditary hemorrhagic telangiectasia].
PubMed 文献 · Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi · 2021-01-01

回顾性分析27例HHT所致家族性鼻出血患者接受静脉贝伐珠单抗(5 mg/kg)治疗,首次治疗后1个月有效率为81.5%(22/27),ESS各维度及标准化评分、全身症状VAS评分均显著下降,血红蛋白显著升高,2例女性出现停经,无其他不良反应。

要点

  • 静脉贝伐珠单抗5 mg/kg治疗HHT相关鼻出血首次后1个月有效率为81.5%。
  • ESS六项及标准化评分、VAS评分均较治疗前显著下降,血红蛋白显著升高。
  • 2例女性首次用药后停经,未见其他不良反应或并发症。

核心结论

  • 静脉滴注贝伐珠单抗治疗HHT所致家族性鼻出血疗效显著且安全性较高。

研究设计与样本

  • 回顾性分析2016年12月至2019年12月三家医院接受静脉贝伐珠单抗治疗的27例HHT所致家族性鼻出血患者,男14例、女13例,年龄(55.3±11.2)岁,剂量按5 mg/kg体重计算,首次治疗后1个月评估疗效。

主要发现

  • 首次治疗后1个月27例中22例鼻出血严重程度明显改善、5例效果不显著,有效率81.5%(22/27)。
  • 效果显著的22例疗效维持5~24个月,中位时间11.23个月。
  • 全身症状VAS评分由(8.19±1.47)分降至(2.41±2.55)分(t=9.708,P<0.01)。
  • ESS标准化评分由(7.60±1.30)分降至(2.50±2.45)分(t=9.344,P<0.01),六个问题得分均显著下降(P<0.01)。
  • 血红蛋白由(73.07±23.71)g/L升至(105.48±24.31)g/L(t=6.864,P<0.01)。

关键数值与推荐

  • 鼻出血频率评分治疗前后为(3.44±0.80)分比(1.78±1.22)分(t=6.814,P<0.01)。
  • 出血持续时间评分为(3.00±0.73)分比(0.85±0.91)分(t=8.845,P<0.01)。
  • 出血强度评分为(1.00±0.00)分比(0.19±0.40)分(t=10.696,P<0.01)。
  • 治疗需求评分为(1.00±0.00)分比(0.22±0.42)分(t=9.539,P<0.01)。
  • 贫血评分为(0.89±0.32)分比(0.41±0.50)分(t=4.914,P<0.01);输血评分为(0.41±0.50)分比(0.11±0.32)分(t=3.309,P<0.01)。

临床怎么用

  • 对HHT所致家族性鼻出血可考虑静脉贝伐珠单抗5 mg/kg治疗,首次后1个月评估疗效。
  • 疗效评估可结合ESS六项评分、ESS标准化评分、全身症状VAS及血红蛋白水平。
  • HHT1型(ENG基因)8例与HHT2型(ACVRL1基因)19例鼻出血改善持续时间分别为(4.76±5.12)个月与(7.60±10.84)个月,HHT2型更长但差异无统计学意义(P>0.05)。

局限性

  • 为回顾性研究,样本量27例,未设对照组。
  • HHT1与HHT2基因型间改善持续时间及ESS评分差异均无统计学意义(P>0.05)。
  • 2例女性首次用药后出现停经,所有患者未出现其他不良反应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To observe the clinical effects of bevacizumab in the treatment of familial epistaxis caused by hereditary hemorrhagic telangiectasia (HHT). Methods: The data of 27 patients with familial epistaxis caused by HHT who were treated with bevacizumab intravenously from Beijing Anzhen Hospital, the First Clinical Center of Chinese People's Liberation Army General Hospital and Binzhou Central Hospital between December 2016 and December 2019 were retrospectively analyzed. There were 14 males and 13 females, aged (55.3±11.2) years. The dose of bevacizumab was calculated according to the body weight of 5 mg/kg. The curative effect was observed one month after the first treatment. Visual analogue scale (VAS) was used to compare patients' self-scores of systemic symptoms before and after treatment. Epistaxis severity score (ESS) was used to compare and analyze the six problems (including the frequency, duration, intensity, treatment demand, anemia and blood transfusion) of the patients before and after treatment. The changes of hemoglobin levels before and after treatment were compared. SPSS 20.0 statistical software was used to process the data. Results: Among the 27 patients at one month after the first bevacizumab treatment, 22 cases reported that the severity of epistaxis was improved significantly, and 5 cases reported that the treatment effect was not significant. The effective rate was 81.5% (22/27). The significant effect in 22 patients lasted for 5-24 months, with a median duration of 11.23 months. The VAS score of systemic symptoms decreased significantly compared with that before treatment (2.41±2.55 vs 8.19±1.47, t=9.708, P<0.01). The scores of six aspects and standardized scores of ESS were significantly decreased after treatment (epistaxis frequency: 1.78±1.22 vs 3.44±0.80, t=6.814, P<0.01; epistaxis duration: 0.85±0.91 vs 3.00±0.73, t=8.845, P<0.01; epistaxis intensity: 0.19±0.40 vs 1.00±0.00, t=10.696, P<0.01; treatment demand: 0.22 ± 0.42 vs 1.00±0.00, t=9.539, P<0.01; anemia: 0.41±0.50 vs 0.89±0.32, t=4.914, P<0.01; blood transfusion: 0.11±0.32 vs 0.41±0.50, t=3.309, P<0.01; ESS standardized score: 2.50±2.45 vs 7.60±1.30, t=9.344, P<0.01). The hemoglobin level after treatment was significantly higher than that before treatment ((105.48±24.31) g/L vs (73.07±23.71) g/L, t=6.864, P<0.01). Among the 27 patients, there were 8 cases of HHT1 (ENG gene) and 19 cases of HHT2 (ACVRL1 gene). The improvement duration of epistaxis in group HHT1 and group HHT2 was (4.76±5.12) months and (7.60±10.84) months, respectively, which was in group HHT2 longer than that of group HHT1, but there was no significant difference between the two groups (P>0.05). There was no significant difference in ESS scores between the two groups before and after treatment (P>0.05). Two female patients had amenorrhea after the first medication. All patients had no other adverse reactions and complications. Conclusion: Intravenous bevacizumab is significantly effective and safe in the treatment of familial epistaxis caused by HHT. 目的: 观察贝伐珠单抗治疗遗传性出血性毛细血管扩张症(hereditary hemorrhagic telangiectasia,HHT)所致家族性鼻出血的临床效果。 方法: 回顾性分析2016年12月至2019年12月期间于北京安贞医院、解放军总医院第一医学中心和滨州医学院附属滨州市中心医院接受静脉滴注贝伐珠单抗治疗的27例HHT所致家族性鼻出血患者的相关资料,其中男性14例,女性13例,年龄(55.3±11.2)岁。按5 mg/kg体重计算贝伐珠单抗剂量,观察第一次用贝伐珠单抗治疗1个月后的疗效。用视觉模拟量表(VAS)对比治疗前后患者全身症状自我评分;用鼻出血严重程度量表(epistaxis severity score,ESS)对治疗前后患者的6个问题(鼻出血频率、持续时间、出血强度、治疗需求、是否贫血、是否输血)进行对比分析;对比治疗前后患者的血红蛋白水平变化情况。采用SPSS 20.0统计软件处理数据。 结果: 第一次贝伐珠单抗治疗1个月后,27例患者中22例自诉鼻出血严重程度明显改善,5例自诉治疗效果不显著,治疗有效率81.5%(22/27)。用药效果显著的22例患者疗效维持时间5~24个月,中位时间11.23个月。全身症状VAS评分较治疗前明显下降,差异有统计学意义[(2.41±2.55)分比(8.19±1.47)分,t=9.708,P<0.01]。ESS的6个问题的得分及ESS标准化评分较治疗前均明显下降[鼻出血频率(1.78±1.22)分比(3.44±0.80)分,t=6.814,P<0.01;出血持续时间(0.85±0.91)分比(3.00±0.73)分,t=8.845,P<0.01;出血强度(0.19±0.40)分比(1.00±0.00)分,t=10.696,P<0.01;治疗需求(0.22±0.42)分比(1.00±0.00)分,t=9.539,P<0.01;是否贫血(0.41±0.50)分比(0.89±0.32)分,t=4.914,P<0.01;是否输血(0.11±0.32)分比(0.41±0.50)分,t=3.309,P<0.01;ESS标准化评分(2.50±2.45)分比(7.60±1.30)分,t=9.344,P<0.01]。治疗后血红蛋白水平较治疗前明显提高,差异有统计学意义[(105.48±24.31) g/L比(73.07±23.71) g/L,t=6.864,P<0.01]。27例患者中HHT1型(ENG基因)8例,HHT2型(ACVRL1基因)19例;药物应用后鼻出血改善持续时间前者为(4.76±5.12)个月,后者为(7.60±10.84)个月,后者长于前者,但差异无统计学意义(P>0.05)。治疗前后ESS评分在两组基因型患者中的差异无统计学意义(P>0.05)。第一次用药治疗后2例女性患者出现停经,所有患者均未出现其他不良反应。 结论: 贝伐珠单抗静脉滴注治疗HHT所致家族性鼻出血疗效显著、安全性高。.

来源:Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi,查看原文。版权归原作者所有。

引用

  1. Zhang J, Wang XS, Wang HT, et al. [Effects of bevacizumab on familial epistaxis caused by hereditary hemorrhagic telangiectasia]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2021. PMID: 34010995. doi:10.3760/cma.j.cn115330-20201222-00939

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。